首页> 外文期刊>Therapeutic Drug Monitoring >Antimicrobial therapy and local toxicity of intraventricular administration of vancomycin in a neonate with ventriculitis.
【24h】

Antimicrobial therapy and local toxicity of intraventricular administration of vancomycin in a neonate with ventriculitis.

机译:新生儿心室炎的室内应用万古霉素的抗菌治疗和局部毒性。

获取原文
获取原文并翻译 | 示例
           

摘要

Infection is the most common complication and cause of failure of cerebrospinal fluid (CSF) shunt devices used to control hydrocephalus. A male newborn was admitted for treatment of congenital occlusive hydrocephalus by means of a ventriculo-peritoneal shunt. A day later, the skin area around the site of insertion of ventriculo-peritoneal catheter was red and edematous. Intravenous ceftazidime and vancomycin were initiated. The shunt was removed but the external ventricular drain was preserved. Blood and CSF cultures showed Enterococcus faecalis sensitive to vancomycin, ciprofloxacin and gentamicin, but resistant to ampicillin. Intraventricular administration of vancomycin 10 mg/24 h was initiated through the external ventricular drain. Before the first dose of vancomycin intraventricularly, CSF levels were 19 mg/dL as a result of administration. On the third day of intraventricular dosing, vancomycin levels in CSF reached 388 mg/dL and protein levels were 1160 mg/dL. On the fifth day of intraventricular treatment the patient had clinically improved and was bacteriologically cured. However, in CSF, protein levels were 3300 mg/dL and vancomycin levels 201 mg/dL. In an attempt to prevent high and potentially toxic levels in CSF, the intraventricular dose of vancomycin should be individualized according to clinical response, bacteriological cultures, vancomycin levels in CSF, and surrogate markers of neurotoxicity, that is, eosinophilia and high protein levels in CSF.
机译:感染是最常见的并发症,是用于控制脑积水的脑脊液(CSF)分流器的故障。一名男新生儿通过脑室-腹膜分流术治疗先天性闭塞性脑积水。一天后,脑室-腹膜导管插入部位周围的皮肤呈红色和水肿。静脉注射头孢他啶和万古霉素。去除了分流管,但保留了外部心室引流。血液和脑脊液培养物显示粪肠球菌对万古霉素,环丙沙星和庆大霉素敏感,但对氨苄西林耐药。通过外部心室引流开始脑室内给予万古霉素10 mg / 24 h。在服用第一剂万古霉素前,经给药后脑脊液水平为19 mg / dL。在脑室内给药的第三天,脑脊液中万古霉素水平达到388 mg / dL,蛋白质水平为1160 mg / dL。在脑室内治疗的第五天,患者的临床状况得到了改善,并通过细菌学治愈。但是,在CSF中,蛋白质水平为3300 mg / dL,万古霉素水平为201 mg / dL。为了防止脑脊液中高和潜在的毒性水平,应根据临床反应,细菌学培养,脑脊液中万古霉素的水平以及替代的神经毒性标志物(即嗜酸性粒细胞增多和脑脊液中高蛋白水平),对脑室内万古霉素的剂量进行个体化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号